PHERGain 试验中 HER2 阳性早期乳腺癌新辅助曲妥珠单抗联合帕妥珠单抗治疗病理完全缓解的最佳 [18F]FDG PET/CT 截断值
PHERGain 试验纳入 285 例 HER2 阳性可手术早期乳腺癌患者,评估代谢影像预测化疗降阶梯的潜力。HP 组 227/285 例(80%)达到预设代谢反应并接受 8 周期 HP 治疗,pCR 率 37.9%。二次预设分析显示 ΔSUVmax 预测 pCR 的 AUC 为 72.1%(95%CI 65.1-79.2%),最佳截断值 77.0%,灵敏度 51.2%、特异度 78.7%,该截断值下 74/285 例(26%)被归为代谢反应者,pCR 率从 37.9%(截断值≥40%)升至 59.5%(44/74 例)(P<0.01)。
要点
- ΔSUVmax 预测 pCR 的 AUC 为 72.1%(95%CI 65.1-79.2%),最佳截断值为 77.0%。
- 截断值 77.0% 时灵敏度 51.2%、特异度 78.7%,74/285 例(26%)归为代谢反应者。
- 截断值≥77% 时 pCR 率 59.5%(44/74 例),高于截断值≥40% 的 37.9%(P<0.01)。
核心结论
- 在 PHERGain 试验中,2 周期单纯 HP(联合或不联合内分泌治疗)后 SUVmax 截断值提高至≥77% 可使 pCR 率达到对照臂化疗联合 HP 的范围(59.5% vs 57.7%),并进一步识别出 HER2 依赖型肿瘤亚组。
- 然而,原始截断值≥40% 可使更多患者免于化疗。
研究设计与样本
- PHERGain 试验的二次预设分析,采用受试者工作特征曲线分析寻找 HER2 阳性早期乳腺癌患者仅接受新辅助 HP(联合或不联合内分泌治疗)时预测 pCR 的最适 ΔSUVmax 截断值。
- 入组 HER2 阳性、浸润性、可手术乳腺癌且至少 1 个乳腺病灶可经 [18F]FDG PET/CT 评估的患者。
- 代谢反应者定义为 2 周期曲妥珠单抗联合帕妥珠单抗(HP,联合或不联合内分泌治疗)后所有靶病灶 SUVmax 下降(ΔSUVmax)至少 40%。
- HP 臂共 285 例患者中 227 例(80%)显示预设代谢反应并接受共 8 周期 HP(联合或不联合内分泌治疗)。
- pCR 定义为 ypT0/isN0,37.9% 的患者达到 pCR。
主要发现
- ΔSUVmax 预测 pCR 的受试者工作特征曲线下面积为 72.1%(95%CI 65.1-79.2%)。
- 最佳 ΔSUVmax 截断值为 77.0%,灵敏度 51.2%,特异度 78.7%。
- 以 77.0% 为截断值,74/285 例(26%)被归为代谢反应者,pCR 率从 37.9%(截断值≥40%)升至 59.5%(44/74 例)(P<0.01)。
- 以优化截断值,44/285 例(15.4%)可在新辅助或辅助阶段免于化疗,而使用原始截断值时为 86/285 例(30.2%)(P<0.001)。
- 优化截断值下 pCR 率为 59.5%(44/74 例),对照臂化疗联合 HP 的 pCR 率为 57.7%。
关键数值与推荐
- 代谢反应预设定义:2 周期 HP(联合或不联合内分泌治疗)后所有靶病灶 ΔSUVmax 至少 40%。
- pCR 定义:ypT0/isN0。
- 最佳 ΔSUVmax 截断值:77.0%(灵敏度 51.2%,特异度 78.7%)。
- AUC:72.1%(95%CI 65.1-79.2%)。
- 截断值≥77% 时 pCR 率 59.5%(44/74 例),截断值≥40% 时 pCR 率 37.9%(P<0.01)。
临床怎么用
- 原文结论指出,截断值≥77% 可使 pCR 率达到对照臂化疗联合 HP 的范围(59.5% vs 57.7%),并进一步识别 HER2 依赖型肿瘤亚组。
- 原文结论指出,原始截断值≥40% 可使最多数量的患者免于化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast lesion evaluable by [18F]FDG PET/CT. [18F]FDG PET/CT responders were defined as patients with an SUVmax reduction (ΔSUVmax) of at least 40% in all of their target lesions after 2 cycles of trastuzumab and pertuzumab (HP) (with or without endocrine therapy). In total, 227 of 285 patients (80%) included in the HP arm showed a predefined metabolic response and received a total of 8 cycles of HP (with or without endocrine therapy). Pathologic complete response (pCR), defined as ypT0/isN0, was achieved in 37.9% of the patients. Here, we describe the secondary preplanned analysis of the best cutoff of ΔSUVmax for pCR prediction. Methods: Receiver-operating-characteristic analysis was applied to look for the most appropriate ΔSUVmax cutoff in HER2-positive early breast cancer patients treated exclusively with neoadjuvant HP (with or without endocrine therapy). Results: The ΔSUVmax capability of predicting pCR in terms of the area under the receiver-operating-characteristic curve was 72.1% (95% CI, 65.1-79.2%). The optimal ΔSUVmax cutoff was found to be 77.0%, with a 51.2% sensitivity and a 78.7% specificity. With this cutoff, 74 of 285 patients (26%) would be classified as metabolic responders, increasing the pCR rate from 37.9% (cutoff ≥ 40%) to 59.5% (44/74 patients) (P < 0.01). With this optimized cutoff, 44 of 285 patients (15.4%) would avoid chemotherapy in either the neoadjuvant or the adjuvant setting compared with 86 of 285 patients (30.2%) using the original cutoff (P < 0.001). Conclusion: In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy.
引用
- Gebhart G, Keyaerts M, Guiot T, et al. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. J Nucl Med. 2024. PMID: 38575192. doi:10.2967/jnumed.123.266384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。